Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained reponse to treatment

European Journal of Gastroenterology and Hepatology

Volumn 9, Issue 12, 1997, Pages 1169-1177

  Bellobuono, Antonio ^a   Mondazzi, Luca ^a   Tempini, Silvana ^a   Silini, Enrico ^b   Idéo, Gaetano ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Chronic hepatitis C; Interferon alpha; Multivariate analysis; Viral hepatitis treatment

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; AMINOTRANSFERASE; LYMPHOBLAST INTERFERON; VIRUS RNA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG COST; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0031458593     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Tinè F, Magrin S, Craxi A, et al.: Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991, 13:192-199.
2. Reichard O, Glaumann H, Norkrans G, et al.: Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Liver 1994, 14:169-174.
3. Shindo M, Di Bisceglie AM, Cheung L, et al.: Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991, 115:700-704.
4. Saracco G, Rosina F, Abate ML, et al.: Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon alfa-2b. Hepatology 1993, 18:1300-1305.
5. Garson JA, Brillanti S, Ring C, et al.: Hepatitis C viremia rebound after 'successful' interferon therapy in patients with chronic non-A, non-B hepatitis. J Med Virol 1992, 37:210-214.
6. Fattovich G, Giustina G, Favarato S, et al.: A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996, 24:38-17.
7. Tsubota A, Chayama K, Ikeda K, et al.: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994, 19:1088-1094.
8. Yoshioka K, Higashi Y, Yamada M, et al.: Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver 1995, 15:57-62.
9. Chemello L, Bonetti P, Cavalletto L, et al.: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995, 22:700-706.
10. Martinol-Peignoux M, Marcellin P, Pouteau M, et al.: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995, 22:1050-1056.
11. Hagiwara H, Hayashi N, Mita E, et al.: Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1943, 104:877-883.
12. Pagliaro L, Craxi A, Cammaà C, et al.:. Interferon alfa for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994, 19:820-828.
13. Matsumoto A, Tanaka E, Suzuki T, et al.: Viral and host factors that contribute to efficacy of interferon-a2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994, 39:1237-1280.
14. Kasahara A, Hayashi N, Hiramatsu N, et al.: Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995, 21:291-297.
15. Poynard T, Bedossa P, Chevallier M, et al.: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995, 332:1457-1462.
16. Okamoto H, Sugiyama Y, Okada S, et al.: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992, 73:673-679.
17. Okamoto H, Tokita H, Sakamoto M, et al.: Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993, 74:2385-2390.
18. Simmonds P, Holmes EC, Cha TA, et al.: Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993, 74:2391-2399.
19. Simmonds P, Alberti A, Alter HJ, et al.: A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994, 19:1321-1324.
20. Silini E, Bono F, Cividini A, et al.: Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995, 21:285-290.
21. Lau JYN, Davis GL, Kniffen J, et al.: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993, 341:1501-1504.
22. Cox DR. The Analysis of Binary Data. London: Methuen: 1970.
23. International Group. Acute and chronic hepatitis revisited. Lancet 1977, ii:914-919.
24. SAS Institute, Inc: SAS/STAT User's Guide. Release 6.04. Cary, NC, USA: SAS Institute, Inc; 1990.
25. Kanai K, Kako M, Aikawa T, et al.: Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype. Liver 1945, 15:185-188.
26. Kanazawa Y, Hayashi N, Mita E, et al.: Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994, 20:1121-1130.
27. Okada S, Akahane Y, Suzuki H, et al.: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992, 16:619-624.
28. Moribe T, Hayashi N, Kanazawa Y, et al.: Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995, 108:789-795.
29. Nousbaum JB, Pol S, Nalpas B, et al.: Hepatitis C virus type 1b (II) infection of France and Italy. Ann Intern Med 1995, 122:161-168.
30. Pozzato G, Kaneko S, Moretti M, et al.: Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994, 43:291-296.
31. Idèo G and the Italian Study Group for Interferon Treatment of Chronic Hepatitis C: An Italian multicentre retrospective study of efficacy of interferon alfa treatment in chronic hepatitis C: preliminary results. Hepatology 1993, 18(4):90A.
32. Jouet P, Roudot-Thoraval F, Dhumeaux D, et al.: Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994, 106:686-690.
33. Reichard O, Foberg U, Frydén A, et al.: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-a 2b for 60 weeks. Hepatology 1994, 19:280-285.
34. De Bac C, Grimaldi F, Clementi C, et al.: Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C. Gut 1993, (suppl.):S135.
35. Honda M, Kaneko S, Sakai A, et al.: Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 1994, 20:1144-1151.
36. Causse X, Godinot H, Chevallier M, et al.: Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991, 101:497-502.